Biolasol: novel perfusion and preservation solution for kidneys.
BACKGROUND
Biolasol solution (Pharmaceutical Research and Production Plant "Biochefa," Sosnowiec, Poland) is a novel extracellular perfusion and ex vivo hypothermic kidney preservation solution. It ensures maintenance of homeostasis, reduces tissue edema, has low viscosity, and allows the graft to preserve structural and functional integrity. It minimizes ischemia-reperfusion damage.


METHODS
Perfundates from control and transplanted kidneys flushed with Biolasol or ViaSpan solutions (Arkas, Warszawa, Poland) were analyzed. Parameters of serum and urine collected from 12 pigs after auto-transplantation were also analyzed. Renal medulla was investigated for structural alterations by analyzing hematoxylin and eosin-stained slides. The mean survival time of pigs after the auto-transplantation procedure was the measure for the novel Biolasol solution effectiveness.


RESULTS
We observed a statistically significant decrease in marker enzyme levels alanine transaminase, aspartate transaminase, lactic dehydrogenase, and ions (Na and K) in pigs with grafts flushed with Biolasol. Histopathologic examination revealed that the renal cortex structure was not damaged after the use of Biolasol solution.


CONCLUSIONS
Biolasol solution protects kidneys against ischemia damage and does not differ significantly from the "golden standard" ViaSpan solution.
Department of General Vascular and Transplant Surgery, Medical University of Silesia, Katowice.
L
L
Cierpka
Pharmaceutical Research and Production Plant Biochefa, Sosnowiec. Electronic address: info@biochefa.pl.
F
F
Ryszka
Pharmaceutical Research and Production Plant Biochefa, Sosnowiec; Department of Applied Pharmacy, Medical University of Silesia, Katowice.
B
B
Dolińska
National Research Institute of Animal Production, Balice.
Z
Z
Smorąg
Institute of Human Genetics PAN, Poznań
R
R
Słomski
Department of Histology & Embryology, Medical University of Silesia, Katowice, Poland.
R
R
Wiaderkiewicz
Department of General Vascular and Transplant Surgery, Medical University of Silesia, Katowice.
A
A
Caban
Department of General Vascular and Transplant Surgery, Medical University of Silesia, Katowice.
G
G
Budziński
Department of General Vascular and Transplant Surgery, Medical University of Silesia, Katowice.
G
G
Oczkowicz
National Research Institute of Animal Production, Balice.
J
J
Wieczorek
D000241:Adenosine / Q000494:pharmacology; D000410:Alanine Transaminase / Q000187:drug effects / Q000378:metabolism; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D001219:Aspartate Aminotransferases / Q000187:drug effects / Q000378:metabolism; D003404:Creatinine / Q000378:metabolism; D005978:Glutathione / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D016030:Kidney Transplantation / Q000379:methods*; D007770:L-Lactate Dehydrogenase / Q000187:drug effects / Q000378:metabolism; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D011044:Poland; D011887:Raffinose / Q000494:pharmacology; D015427:Reperfusion Injury / Q000517:prevention & control*; D013552:Swine; D014182:Transplantation, Autologous
D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose